Intelligence Platform
Patents
Browse 202 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 12410430
Modulating apolipoprotein (A) expression
granted patentUS 12409188
Modulators of HSD17B13 expression
granted patentUS 12350285
Compounds and methods for reducing ATXN3 expression
granted patentUS 12343357
Compositions and methods for modulating MECP2 expression
granted patentUS 12297431
Modulation of huntingtin expression
granted patentUS 12291709
Compositions and methods for modulating apolipoprotein (a) expression
granted patentUS 12281305
Compounds and methods for reducing prion expression
granted patentUS 12275940
Conjugated antisense compounds and their use
granted patentUS 12241067
Compounds and methods for reducing LRRK2 expression
granted patentUS 12227746
Compounds and methods for modulating SCN2A
granted patentUS 12215321
Modulators of diacyglycerol acyltransferase 2 (DGAT2)
granted patentUS 12188020
Methods for reducing Ataxin-2 expression
granted patentUS 12180479
Compounds and methods for modulating ATXN1
granted patentUS 12152244
Selective antisense compounds and uses thereof
granted patentUS 12115225
GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
granted patentUS 12110491
Selective reduction of allelic variants
granted patentUS 12043831
Modulation of alpha synuclein expression
granted patentUS 12042510
Modulators of IRF4 expression
granted patentUS 12030910
Compounds and methods for the modulation of proteins
granted patentUS 12018261
Compounds and methods for modulating factor XII
granted patentUS 11981897
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) express
granted patentUS 11959080
Methods and compositions for inhibiting PMP22 expression
granted patentUS 11926830
Modulators of Complement Factor B
granted patentUS 11926825
Compounds and methods for reducing ATXN2 expression
granted